European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Thermal Evaluation of specific drug delivery with Molecularly imprinted nanoParticles developed against Estrogen Receptor

Descrizione del progetto

Un nanovettore di farmaci semplice ma specifico

La mortalità correlata al carcinoma mammario nei paesi in via di sviluppo è superiore rispetto a quella dei paesi ad alto reddito e questo dato indica che il trattamento non raggiunge le aree economicamente svantaggiate. Per affrontare questo problema, il progetto TEMPER, finanziato dall’UE, propone di sviluppare nanovettori polimerici di farmaci che presentano specificità ed efficacia di intervento più elevate senza provocare gli effetti collaterali comuni dei farmaci convenzionali. Questi nanovettori saranno estremamente versatili e idonei ad essere personalizzati per somministrare qualsiasi farmaco scelto, tra cui gli antibiotici contro le infezioni, o utilizzabili per scopi diagnostici. La semplicità e la convenienza dell’approccio di somministrazione farmacologica di TEMPER garantirà la sua applicabilità nei paesi in via di sviluppo.

Obiettivo

Breast cancer is the most commonly occurring cancer in women with over two million new cases reported in 2018. It is a genetically diverse disease with each type requiring different treatment. In developing countries, the highest amount of female cancer deaths are attributed to breast cancer with substantially lower survival rates compared to the western world. Therefore, the aim of this proposal is to develop polymeric drug nanocarriers that can improve drug efficacy, and thereby have potential to make cancer treatment available to all layers of the population including those living in deprived areas. We will develop high affinity nanoparticles that can selectively bind to certain receptors on the surface of cancer cells. When attached, the nanocarriers will release their cargo (drug compounds) specifically to the tumour and thereby improve drug efficacy and subsequently patient outcome. Furthermore, it will reduce adverse effects of common anti-cancer drugs including nausea, fatigue, hepatitis and high vulnerability to endometrial cancer. The drug delivery is usually monitored with optical techniques but the novelty of this project is to use thermal analysis, which is label-free and simple to use. The polymeric nanocarriers are highly versatile and by changing the composition, we can tailor this platform to other drug compounds or other cancer types. In addition, it has high potential as a diagnostic tool in high-throughput drug testing, customization of cellular therapy, and combating bacterial infections. This project could bring tremendous benefits in cancer treatment particularly in developing countries such as India due to its low-cost and simplicity.

Coordinatore

UNIVERSITY OF NEWCASTLE UPON TYNE
Contribution nette de l'UE
€ 224 933,76
Indirizzo
KINGS GATE
NE1 7RU Newcastle Upon Tyne
Regno Unito

Mostra sulla mappa

Regione
North East (England) Northumberland and Tyne and Wear Tyneside
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 224 933,76